To make the world smarter, happier, and richer. Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches ...

Late Friday, the U.S. FDA granted De Novo marketing authorization for the Invitae Common Hereditary Cancers Panel. The panel is the first of its kind to receive FDA marketing authorization. Invitae is ...

Its been a big, albeit wholly erratic, year for Invitae (NYSE: NVTA), one of the tech stock winners of 2020. On March 19, 2020, the stock sat at $7.43. In mid-December, it topped $61. Now, after a ...

Shares of San Francisco-based genetic testing and data company Invitae Corporation (NVTA) exploded higher after reporting earnings Tuesday night. After 6.5 trading hours on Wednesday, Invitae stock ...

Within the last quarter, Invitae (NYSE:NVTA) has observed the following analyst ratings: These 5 analysts have an average price target of $7.2 versus the current price of Invitae at $2.675, implying ...

Invitae is a growth leader in genetic testing. The company is growing at full speed, and it has enormous room for expansion going forward. Lack of profitability and share dilution are the main ...

Invitae Corporation faces significant challenges in addressing its liquidity concerns. Invitae has entered into an Asset Purchase Agreement with Natera, involving the sale of specific assets in the ...

The stock's recent peak comes amid historically low implied volatility The shares of InVitae Corp (NYSE: NVTA) are down 7.6% to trade at $34.23 at last check, just one day after hitting a record high ...